微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > gemcitabine plus cisplatin
gemcitabine plus cisplatin

肿瘤

关键词肿瘤 治疗方法 化疗

词汇介绍

拓展阅读

解析

Gemcitabine 

释    义   n. 吉西他滨或胞苷或健泽(药物名)

例    句   Many pancreatic tumor cells are resistant to gemcitabine, which makes the disease very difficult to treat. 很多胰腺肿瘤细胞对吉西他滨耐药,导致这种疾病现在很难得到有效治疗。

 

Plus   英 /plʌs/   美 /plʌs; pluː/

释    义   prep. 加;和;(温度)零上

               adj. (用于数字后表数量大)余;零上;好的;略高于(A、B等分数);正电的

               n. 优势;加号;加法;附加额

               conj. (非正式)而且,另外;加

例    句   It is the value plus or minus something. 它是某个值的正负。

 

cisplatin   /sis'plætən/  

释    义   n. 铂化合物,顺铂;顺氯氨铂

例    句   For 30 years, the chemotherapy drug cisplatin has been one of doctors’ first lines of defense against tumors, especially those of the lung, ovary and testes. 30年来,化疗药物顺铂一直是医生常用的一线抗肿瘤药物之一,尤其是对抗肺部、子宫和睾丸的肿瘤。

概述

吉西他滨,简称GEM(Gemcitabine),为一种新的胞嘧啶核苷衍生物,属于核苷酸还原酶抑制剂,进入人体内后由脱氧胞嘧啶激酶活化,由胞嘧啶核苷脱氨酶代谢。在细胞内经核苷激酶被代谢为具有活性的二磷酸(dFdCDP)及三磷酸核苷(dFdCTP)。dFdCDP抑制核苷酸还原酶的活性,使合成DNA所必需的三磷酸脱氧核苷的生成受到抑制。dFdCTP与dCTP竞争掺入至DNA链中(自增强作用)。少量的吉西他滨还可以掺入RNA分子中。吉西他滨属于细胞周期特异性药物,主要作用于S期,可阻止G1期向S期转

Response Rate Following Albumin-Bound Paclitaxel Plus Gemcitabine Plus Cisplatin Treatment Among Patients With Advanced Pancreatic Cancer复制标题

白蛋白结合型紫杉醇联合吉西他滨联合顺铂治疗晚期胰腺癌患者的疗效

发表时间:2019-10-03

影响因子:22.4

作者: Gayle S. Jameson

期刊:JAMA Oncol

IMPORTANCE: Genomes of metastatic pancreatic cancers frequently contain intrachromosomal aberrations, indicating a DNA repair deficiency associated with sensitivity to DNA damaging agents, such as platinum. OBJECTIVE: To determine response rate following treatment with nab-paclitaxel plus gemcitabine plus platinum-based cisplatin for patients with metastatic pancreatic ductal adenocarcinoma (PDA). DESIGN, SETTING, AND PARTICIPANTS: This was a single-arm, open-label, phase 1b/2 clinical trial of nab-paclitaxel plus gemcitabine plus cisplatin treatment in which 25 patients with previously untreated metastatic PDA were enrolled. The trial was conducted from December 2013 to July 2016 at 3 US sites, with the last patient receiving study treatment at the end of October 2016, and the study closing January 2018. INTERVENTIONS: Patients were treated with nab-paclitaxel plus gemcitabine plus various doses of cisplatin, 25 mg/m2, 37.5 mg/m2, and 50 mg/m2, on days 1 and 8 of a 21-day cycle. MAIN OUTCOMES AND MEASURES: Primary end point was complete response rate as assessed by Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST), and levels of carbohydrate antigen 19-9 (or in nonexpressers, carbohydrate antigen 125 or carcinoembryonic antigen). Efficacy analysis included evaluable patients (those who received at least 1 dose of study treatment and had at least 1 postbaseline tumor assessment).

译文

重要意义:转移性胰腺癌的基因组常含有染色体内畸变,表明DNA修复缺陷与对DNA损伤剂(如铂)的敏感性有关。目的:探讨纳布紫杉醇联合吉西他滨联合铂类顺铂治疗转移性胰腺导管腺癌(PDA)的疗效。设计,设置,和参与者:这是单臂,开放标签,阶段1B / 2临床试验的NAB紫杉醇+吉西他滨联合顺铂治疗,其中25例以前未治疗的转移性PDA登记。试验于2013年12月至2016年7月在美国3个地点进行,最后一名患者在2016年10月底接受研究治疗,研究于2018年1月结束。干预措施:在21天周期的第1天和第8天,患者接受纳布紫杉醇加吉西他滨加不同剂量的顺铂(25 mg/m2、37.5 mg/m2和50 mg/m2)治疗。主要结果和措施:主要终点是通过反应评估标准评估实体瘤1.1版(RECIST)和碳水化合物抗原19-9水平(或非表达者、碳水化合物抗原125或癌胚抗原)的完全反应率。疗效分析包括可评价的患者(那些接受至少1剂研究治疗且至少有1次基线后肿瘤评估的患者)。